Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

woman is pain via Shutterstock
Breakthrough

New treatment for most common type of arthritis could be here in 5 years

Around 400,000 people in Ireland suffer from osteoarthritis.

SCIENTISTS AT GALWAY University have achieved positive results from a study looking to cure osteoarthritis.

Early results from the stem cells study indicates that the research could be used on patients within five years.

Osteoarthritis affects over 400,000 people in Ireland and more than 70 million in the EU.

It is the most common form of arthritis. It causes the painful degeneration of cartilage in joints.

The researchers are looking at how stem cells from adult fat tissue could be used to activate the regeneration of cartilage.

The Phase 1 clinical trial has just finished.

Professor Frank Barry, Scientific Director of the Regenerative Medicine Institute at NUI Galway said,

“Until now there were just two possible outcomes for suffers of this progressive and debilitating disease; joint replacement surgery, in the case of advanced disease or, life-long pain management.

Whilst we are still in the early stages of clinical trials the results so far are extremely positive such that the use of stem cell therapy for osteoarthritis could become a reality for patients within the next 5 years.

The research is EU funded and is being carried out in seven countries.

Read: Stem cells for human use can now be manufactured in Ireland>

Read: New findings may provide relief for osteoarthritis sufferers>

Your Voice
Readers Comments
6
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.